Plus Therapeutics Stock Soars 47.04% Despite Earnings Miss

Plus Therapeutics' stock surged 47.04% in pre-market trading on June 2, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Plus Therapeutics reported a quarterly loss of $1.19 per share for the first quarter of 2025, which fell short of the analyst consensus estimate of $0.25 by a substantial 376%. The Houston-based company recorded a net loss of $17.4 million for the quarter, highlighting the financial challenges it faces.

The company's revenue for the quarter was $1.06 million, which also missed the expected revenue by $0.08 million. This earnings miss has raised concerns among investors about the company's financial health and its ability to meet future earnings expectations.

Despite the disappointing earnings report, the significant pre-market surge in Plus Therapeutics' stock price suggests that investors may be looking beyond the current quarter's performance and focusing on the company's long-term prospects and potential for growth.